2014 Parkinson Study Group Symposium and Training

2014年帕金森研究组研讨会及培训

• 批准号: 8838558
• 负责人: MICHAEL A SCHWARZSCHILD
• 金额: $ 2万
• 依托单位: MASSACHUSETTS GENERAL HOSPITAL
• 依托单位国家: 美国
• 财政年份: 2014
• 资助国家: 美国
• 起止时间: 2014-09-22 至 2015-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8838558
• 关键词: Address; Advocate; Affect; Animal Model; Ataxia; Caring; Characteristics; Clinical; Clinical Investigator; Clinical Research; Clinical Trials; Collaborations; Development; Disease; Doctor of Philosophy; Dystonia; Education; Educational Activities; Educational workshop; Ensure; Etiology; Family; Fostering; Foundations; Gilles de la Tourette syndrome; Goals; Grant; Huntington Disease; Intervention; Investments; Isradipine; Knowledge; Life; Logistics; Mechanics; Mentors; Missouri; Modification; Movement Disorders; Multi-Institutional Clinical Trial; National Institute of Neurological Disorders and Stroke; Neurodegenerative Disorders; Neurology; Outcome Study; Parkinson Disease; Pathogenesis; Patient Care; Patients; Peer Review; Pharmacological Treatment; Randomized Clinical Trials; Research; Research Activity; Research Design; Research Personnel; Research Proposals; Scientist; Site; Staging; Therapeutic Clinical Trial; Training; Training and Education; Translational Research; Tremor; Writing; career; career development; clinical practice; design; experience; frontier; improved; insight; meetings; nervous system disorder; novel; patient oriented; posters; programs; public health relevance; symposium; therapeutic target

 DESCRIPTION (provided by applicant): The proposed conference project, centered on the annual clinical research symposium of the Parkinson Study Group (PSG) and associated annual meeting activities, will foster the education and training of early stage investigators to ensure that the highest quality translational and clinical research continues to be conducted toward improved therapy for Parkinson's and related neurological diseases. This project goal will be achieved through two specific aims (SAs). In SA #1, the PSG will present the "28th Annual Symposium on Etiology, Pathogenesis, and Treatment of Parkinson's Disease and Other Movement Disorders" in collaboration with the Huntington Study Group (HSG), Dystonia Study Group (DSG), Tourette Syndrome Study Group (TSSG), Cooperative Ataxia Group (CAG), and Tremor Research Group (TRG) on Friday, September 19, 2014 in St. Louis, Missouri. The peer-reviewed program includes both platform and poster presentations in a live format with audience participation. The symposium will consist of current issues in movement disorders with keynote talks on disease modification focusing on new therapies and peer-reviewed platform and poster presentations on movement disorders including Parkinson disease (PD), Huntington disease, Dystonia, Ataxia, and Tremor. Topics are designed to communicate recent research advances, including new pharmacological and non-pharmacological treatment options in the field of movement disorders thereby enhancing patient care. The gaps in clinical practice to address are the unmet needs pertaining to the translational and clinical research, along with the care and treatment of patients and families affected by movement disorders. SA #2 is designed to provide early-stage clinical investigators with movement disorders training and a multi-faceted practical orientation to PD clinical research. The selected junior investigators will participate i several novel and interactive, educational research activities in addition to the symposium, including a) direct exchange with experienced patient advocates of the Parkinson's Disease Foundation's PAIR (Parkinson's Advocates in Research) program over collaborative strategies to improve clinical research by incorporating patient perspectives; b) the PSG Mentoring Committee's junior investigator career development workshop; c) the investigator orientation meeting of the NINDS-supported STEADY-PD3 study, a 56-site randomized clinical trial of a candidate disease-modifying neurotherapeutic, offering a valuable introduction to the rationale and mechanics underlying clinical trial development. Junior investigators completing participation in the project will be substantially better prepared and motivated to pursue careers and studies in clinical neurology.

 描述（由申请人提供）：拟议的会议项目以帕金森研究组（PSG）年度临床研究研讨会和相关年会活动为中心，将促进早期研究人员的教育和培训，以确保继续进行最高质量的转化和临床研究，以改善帕金森病和相关神经系统疾病的治疗。该项目目标将通过两个具体目标 (SA) 来实现。在 SA #1 中，PSG 将于 2014 年 9 月 19 日星期五在圣路易斯与亨廷顿研究组 (HSG)、肌张力障碍研究组 (DSG)、抽动秽语综合征研究组 (TSSG)、合作共济失调组 (CAG) 和震颤研究组 (TRG) 合作，举办“第 28 届帕金森病和其他运动障碍的病因学、发病机制和治疗年度研讨会”。 密苏里州路易斯。同行评审的节目包括以现场形式进行的平台展示和海报展示，并有观众参与。研讨会将讨论运动障碍的当前问题，并就疾病修饰进行主题演讲，重点讨论新疗法和同行评审的平台以及关于运动障碍的海报演示，包括帕金森病 (PD)、亨廷顿病、肌张力障碍、共济失调和震颤。主题旨在传达最新的研究进展，包括运动障碍领域的新药理学和非药物治疗方案，从而加强患者护理。临床实践中需要解决的差距是与转化和临床研究以及受运动障碍影响的患者和家庭的护理和治疗相关的未满足的需求。 SA #2 旨在为早期临床研究人员提供运动障碍培训和 PD 临床研究的多方面实践指导。除了研讨会之外，选定的初级研究人员还将参加一些新颖的、互动的、教育性的研究活动，包括：a）与帕金森病基金会 PAIR（帕金森病研究倡导者）计划的经验丰富的患者倡导者直接交流，探讨通过纳入患者观点来改进临床研究的合作策略； b) PSG 指导委员会初级研究员职业发展研讨会； c) NINDS 支持的 STEADY-PD3 研究的研究者说明会，该研究是一项针对候选疾病缓解神经治疗药物的 56 个中心随机临床试验，为临床试验开发的基本原理和机制提供了有价值的介绍。完成该项目参与的初级研究人员将有更好的准备和动力去从事临床神经病学的职业和研究。